DailyIQ
Last updated 5 minutes ago

VRTX·Vertex Pharmaceuticals Incorporated

$.
-. (-.%)
After Hours
High
$498.49
Open
$498.21
Market Cap
121.15B
52W High
$533.67
Low
$484.33
P. Close
$485.29
P/E
27.92
52W Low
$362.50
Fwd P/E
22.86
DailyIQ Est.
$581.61
Technical Score (1D)
68
BUY
News Sentiment
81
BULLISH
Vertex’s announcement of a $10 billion acquisition of Crinetics Pharmaceuticals marks a significant shift in its product pipeline, adding the approved oral therapy PALSONIFY for acromegaly and the late‑stage candidate atumelnant for congenital adrenal hyperplasia to its portfolio. The deal, priced at $85 per share, signals Vertex’s intent to broaden its endocrinology franchise, a move that could diversify revenue streams beyond its current focus on cystic fibrosis and oncology. Because the transaction is expected to close in Q3 2026, the immediate financial impact on earnings is projected to be modest, with management forecasting accretion to non‑GAAP operating income only by 2029. This near‑term neutrality means the stock should not experience a dramatic price swing in the next 1–10 trading days, but the announcement may still influence short‑term sentiment as investors reassess the company’s growth prospects. The financing structure—combining cash, debt, and a $4.5 billion bridge—could affect VRTX’s balance sheet and cost of capital, potentially tightening liquidity and raising debt ratios. Watch for any updates on the regulatory review process, as delays or objections could alter the closing timeline and the perceived value of the endocrine assets. Additionally, keep an eye on any early-stage clinical data releases for atumelnant, which could provide a clearer picture of its commercial viability and risk profile. Finally, monitor broader market reactions to similar biotech acquisitions, as sector-wide sentiment may amplify or dampen the impact of Vertex’s deal on its share price.
Earnings Summary
Vertex Pharmaceuticals is a biotechnology company focused on developing and commercializing innovative therapies, with a strong emphasis on cystic fibrosis treatments such as TRIKAFTA/KAFTRIO and a growing pipeline in rare diseases. The company operates in the healthcare sector, delivering specialty pharmaceuticals through a network of distributors and specialty pharmacies. In Q4 2024 Vertex reported earnings per share of $3.98 versus an estimate of $4.02 and revenue of $2.91 billion, slightly missing consensus; the following quarter, Q1 2025, the company again missed EPS expectations with $4.06 against an estimate of $4.29 while revenue rose to $2.77 billion, reflecting modest top‑line growth. Q2 2025 saw a reversal with EPS of $4.52 beating an estimate of $4.25 and revenue of $2.96 billion, followed by Q3 2025 where EPS climbed to $4.80 versus an estimate of $4.58 and revenue reached $3.08 billion. The most recent quarter, Q4 2025, delivered EPS of $5.03 against an estimate of $5.17 and revenue of $3.19 billion, a 10.4% year‑over‑year increase, while Q1 2026 posted EPS of $4.47 beating an estimate of $4.39 and revenue of $2.99 billion, a decline from the prior quarter. Historically, Vertex has posted double‑digit revenue growth each year, with EPS rising from $3.98 in 2024 to $5.03 in 2025, and the company has maintained a streak of consecutive revenue increases since 2019, though it has experienced a mix of EPS beats and misses. Recent news highlights the FDA approval of CASGEVY for children as young as two, expanding Vertex’s pediatric mandate, and the $10 billion all‑cash acquisition of Crinetics, adding late‑stage assets that could broaden its revenue base. Investors should watch the upcoming earnings guidance for commentary on CASGEVY commercial rollout timelines, reimbursement decisions, and the integration progress of Crinetics, as these factors will shape the company’s near‑term valuation and earnings trajectory.

EPS

EstBeatMiss
$3.89$4.25$4.61$4.97$5.33Q1'25Q2'25Q3'25Q4'25Q1'26Q2'26
QtrEstActual+/−
Q2'26$4.73 - -
Q1'26$4.39$4.47+1.7%
Q4'25$5.17$5.03-2.7%
Q3'25$4.58$4.80+4.9%
Q2'25$4.25$4.52+6.3%
Q1'25$4.29$4.06-5.4%

Revenue

EstBeatMiss
$2.7B$2.9B$3.0B$3.2B$3.4BQ1'25Q2'25Q3'25Q4'25Q1'26Q2'26
QtrEstActual+/−
Q2'26$3.3B - -
Q1'26$3.1B$3.0B-3.4%
Q4'25$3.2B$3.2B-1.5%
Q3'25 - $3.1B -
Q2'25 - $3.0B -
Q1'25 - $2.8B -

Market Data

VRTX Stock Snapshot

VRTX is currently trading at $487.29, giving Vertex Pharmaceuticals Incorporated a market cap of 121.15B and a P/E ratio of 27.9. Today's range spans $484.33–$498.49, with shares opening at $498.21 and moving up $2.00 (0.4%) from the prior close. DailyIQ's technical score sits at 68/100 (BUY) with a news sentiment reading of 81/100.

Over the past year VRTX has traded between $362.50 and $533.67 - the current price is +34.4% off the 52-week low and -8.7% from the high. 41 analysts cover the stock with a Buy consensus and a mean 12-month target of $554.56 (range $350.00–$641.00), implying upside of +13.8%.

What VRTX has right now - BUY signal, 68/100 technical score, bullish sentiment at 81/100, price $487.29 (in the upper portion of its 52-week range) - is the profile that shows up in screens looking for Healthcare growth stories with technical confirmation. (P/E: 27.9) At 121.15B in capitalization, the risk/reward of a setup like this is often better than in mega-cap peers where the same signal translates to a smaller percentage move. Range: $362.50–$533.67.

The combination of a BUY signal (68/100) and bullish news sentiment (81/100) puts VRTX on the screens of active managers who run quality-momentum overlays — a cohort that can build meaningful positions at 121.15B in Healthcare market cap without immediately moving the stock. At $487.29 (in the upper portion of its 52-week range in the $362.50–$533.67 range), the entry discipline is clean and the potential re-rating if sentiment continues to improve is meaningful.